Cargando…

A randomized, double‐blind, placebo‐controlled, phase 3 study of tivantinib in Japanese patients with MET‐high hepatocellular carcinoma

A previous randomized phase 2 study of hepatocellular carcinoma revealed that the c‐Met inhibitor tivantinib as second‐line treatment significantly prolonged progression‐free survival in a subpopulation whose tumor samples highly expressed c‐Met (MET‐high). Accordingly, this phase 3 study was conduc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kudo, Masatoshi, Morimoto, Manabu, Moriguchi, Michihisa, Izumi, Namiki, Takayama, Tetsuji, Yoshiji, Hitoshi, Hino, Keisuke, Oikawa, Takayoshi, Chiba, Tetsuhiro, Motomura, Kenta, Kato, Junko, Yasuchika, Kentaro, Ido, Akio, Sato, Takashi, Nakashima, Daisuke, Ueshima, Kazuomi, Ikeda, Masafumi, Okusaka, Takuji, Tamura, Kazuo, Furuse, Junji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541009/ https://www.ncbi.nlm.nih.gov/pubmed/32716114 http://dx.doi.org/10.1111/cas.14582

Ejemplares similares

Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors
por: Okusaka, Takuji, et al.
Publicado: (2015)

Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
por: Kudo, Masatoshi, et al.
Publicado: (2022)

Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON
por: Kudo, Masatoshi, et al.
Publicado: (2016)

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
por: Kudo, Masatoshi, et al.
Publicado: (2020)

Development of Tivantinib as Treatment for Hepatocellular Carcinoma
por: Au, Jennifer, et al.
Publicado: (2013)

Clinical Practice Guidelines for Hepatic Arterial Infusion Chemotherapy with a Port System Proposed by the Japanese Society of Interventional Radiology and Japanese Society of Implantable Port Assisted Treatment
por: Ueshima, Kazuomi, et al.
Publicado: (2022)

Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107
por: Twardowski, Przemyslaw W., et al.
Publicado: (2017)

Targeted Therapy for Biliary Tract Cancer
por: Furuse, Junji, et al.
Publicado: (2011)

Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines
por: Okusaka, Takuji, et al.
Publicado: (2020)

Application of Tivantinib for Hepatocellular Carcinoma: A Meta-Analysis Study
por: Luo, Guang-li, et al.
Publicado: (2022)

Tivantinib alleviates inflammatory diseases by directly targeting NLRP3
por: Huang, Yi, et al.
Publicado: (2023)

Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date
por: Pievsky, Daniel, et al.
Publicado: (2016)

Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia
por: Kuenzi, Brent M., et al.
Publicado: (2019)

The effectiveness of tivantinib for MET-high hepatocellular carcinoma: A protocol for meta analysis
por: Wang, Yubin, et al.
Publicado: (2023)

Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial
por: Kudo, Masatoshi, et al.
Publicado: (2020)

Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors
por: Puzanov, Igor, et al.
Publicado: (2014)

The efficacy and safety of tivantinib in the treatment of solid tumors: a systematic review and meta-analysis
por: Zhang, Hao, et al.
Publicado: (2017)

Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan
por: Furuse, Junji, et al.
Publicado: (2023)

Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer
por: Broggini, Massimo, et al.
Publicado: (2013)

Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma
por: Xiang, Qingfeng, et al.
Publicado: (2015)

Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer
por: Tolaney, Sara M., et al.
Publicado: (2015)

Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma
por: Wei, Kai, et al.
Publicado: (2019)

Eosinophilic Cholangitis with Poor Prognosis after Corticosteroid- and Ursodeoxycholic Acid-Related Remission of Peripheral and Peribiliary Eosinophilia
por: Shimomura, Takahito, et al.
Publicado: (2021)

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis
por: Santoro, A, et al.
Publicado: (2013)

Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib
por: Agwa, Eberechi S, et al.
Publicado: (2014)

Targeting the Pro-Survival Protein MET with Tivantinib (ARQ 197) Inhibits Growth of Multiple Myeloma Cells()()
por: Zaman, Shadia, et al.
Publicado: (2015)

Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance
por: Wu, Zhuo-Xun, et al.
Publicado: (2020)

Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors
por: Kummar, Shivaani, et al.
Publicado: (2021)

Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis
por: Furuse, Junji, et al.
Publicado: (2017)

Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives
por: Hijioka, Susumu, et al.
Publicado: (2021)

Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial
por: Okita, Kiwamu, et al.
Publicado: (2014)

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib
por: Rimassa, Lorenza, et al.
Publicado: (2016)

Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
por: Zhao, Shankun, et al.
Publicado: (2021)

Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial
por: Furuse, Junji, et al.
Publicado: (2022)

Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma
por: Baljevic, Muhamed, et al.
Publicado: (2017)

Tivantinib Hampers the Proliferation of Glioblastoma Cells via PI3K/Akt/Mammalian Target of Rapamycin (mTOR) Signaling
por: Wu, Yukun, et al.
Publicado: (2019)

Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
por: Okusaka, Takuji, et al.
Publicado: (2015)

Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
por: Okusaka, Takuji, et al.
Publicado: (2014)

First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2018)

A Review of Non-operative Treatments for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombus
por: Moriguchi, Michihisa, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_t2lhofj41qdnb4aa180oma7slc